guselkumab vs picankibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02203032 · Phase 3 · completed

In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.

Next expected readout: December 2026 · NCT05004727 (registry estimate)

Reported efficacy

Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)

Result source: NCT02203032

picankibart

Marketed by Innovent Biologics

Phase 3 in Psoriasismonoclonal antibody (anti-IL-23p19)
Reliable signal

NCT05645627 · Phase 3 · completed

CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.

Reported efficacy

Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)

Result source: NCT06049810

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabpicankibart
PASI 7584.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
—Not posted · NCT05645627
PASI 9070% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
80.3% vs 2%a+78.3 vs placebowk 16NCT05645627
PASI 10050% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
—Not posted · NCT05645627
sPGA 0/185.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
—Not posted · NCT05645627
DLQI, change-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
—Not posted · NCT05645627

PASI 75

guselkumab
84.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
picankibart
—Not posted · NCT05645627

PASI 90

guselkumab
70% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
picankibart
80.3% vs 2%a+78.3 vs placebowk 16NCT05645627

PASI 100

guselkumab
50% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
picankibart
—Not posted · NCT05645627

sPGA 0/1

guselkumab
85.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
picankibart
—Not posted · NCT05645627

DLQI, change

guselkumab
-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
picankibart
—Not posted · NCT05645627
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. guselkumab: 5 of 5 rows · picankibart: 1 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Rows use multiple source trials
picankibart
Rows use multiple source trials
PASI 90 Response Maintenance
responder rate · % of participants
Maintenance
85.2% (n=54) vs 35.7% (n=14) Fumaric Acid Esters @ 56wka,b
NCT02951533 · Phase 3 · registry result, not featured evidence
90.1% vs 51.7% corresponding randomized-withdrawal group @ 56wk200 mg picankibart-maintenancec,a,b
NCT06049810 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
89.3% vs 37.7% corresponding randomized-withdrawal group @ 56wk100 mg picankibart-maintenance
NCT06049810 · Phase 3 · sponsor-reported, not registry data
Dropout rate
—100 mgd
NCT02203032 · Phase 3
show 42 more results
3.6%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
1.6%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
9.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
13%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
7.6%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
3.1%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
4.8%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—
Discontinued due to AEs
—100 mgd
NCT02203032 · Phase 3
show 42 more results
1.8%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
0%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
1.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
1.3%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
1.9%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—
Serious AEs
6.7%100 mgd
NCT02203032 · Phase 3
show 42 more results
1.6%100 mg
NCT02207244 · Phase 3
2.1%100 mg
NCT02207244 · Phase 3
14%100 mg
NCT02207244 · Phase 3
2.5%100 mg
NCT02207231 · Phase 3
2.4%100 mg
NCT02207231 · Phase 3
—Guselkumab
NCT02905331 · Phase 3
3.2%Guselkumab (Week 0-16)
NCT02905331 · Phase 3
1.6%Guselkumab (Week 16-40)
NCT02905331 · Phase 3
3.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
3.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
5.3%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
4.7%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.3%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
2.2%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
3.5%100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4.3%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
0%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
9.7%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
9.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
5%Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
0%Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
5.5%Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
6.2%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—
Most frequent reported AEs
100 mgd
nasopharyngitis 17%
upper respiratory tract infection 11.1%
NCT02203032 · Phase 3
show 37 more results
100 mg
nasopharyngitis 7.1% (placebo 6.5%)
headache 5.1% (placebo 2.8%)
upper respiratory tract infection 3.2% (placebo 4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 3.7% (placebo 6.5%)
upper respiratory tract infection 2.5% (placebo 4%)
arthralgia 1.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 30% (placebo 6.5%)
upper respiratory tract infection 23.5% (placebo 4%)
arthralgia 9.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 20.1% (placebo 9.8%)
upper respiratory tract infection 9.6% (placebo 5.2%)
gastroenteritis 3.4% (placebo 1.1%)
NCT02207231 · Phase 3
100 mg
nasopharyngitis 9.1% (placebo 9.8%)
upper respiratory tract infection 7.6% (placebo 5.2%)
headache 4.3% (placebo 4%)
NCT02207231 · Phase 3
injection site pain 40.3% (placebo 43.8%)
injection site coldness 22.6% (placebo 18.8%)
injection site pruritus 12.9% (placebo 12.5%)
NCT02905331 · Phase 3
injection site pain 18% (placebo 43.8%)
injection site coldness 11.5% (placebo 18.8%)
viral upper respiratory tract infection 9.8% (placebo 0%)
NCT02905331 · Phase 3
upper respiratory tract infection 8.1%
nasopharyngitis 5.3%
injection site reaction 1.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 16.9% (placebo 3.8%)
nasopharyngitis 11.7% (placebo 3.8%)
covid-19 6.5% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 24.7% (placebo 3.8%)
covid-19 16% (placebo 0%)
arthralgia 7.4% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 15.1% (placebo 2.7%)
nasopharyngitis 6.7% (placebo 7.1%)
covid-19 4.4% (placebo 0.9%)
NCT06039189 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 17.6%
headache 5.4%
back pain 4.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 18.5%
hypertension 5.9%
arthralgia 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
covid-19 14.7%
nasopharyngitis 12.5%
psoriasis 7.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 14.1%
covid-19 9.3%
headache 5.7%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 24.3%
headache 9%
hypertension 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nail psoriasis 22.2%
back pain 11.1%
covid-19 11.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 15.4%
headache 6%
back pain 5.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 12.4%
covid-19 8.8%
psoriasis 8.8%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 50% (placebo 10.9%)
eczema 11.3% (placebo 1.6%)
injection site erythema 11.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 12.7% (placebo 10.9%)
dental caries 3.2% (placebo 1.6%)
upper respiratory tract infection 3.2% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 60.3% (placebo 10.9%)
arthralgia 14.3% (placebo 0%)
influenza 14.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 21.5% (placebo 10.9%)
alopecia 3.1% (placebo 0%)
arthralgia 3.1% (placebo 0%)
NCT02325219 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.7%
headache 15%
diarrhoea 11.7%
NCT02951533 · Phase 3 · registry result, not featured evidence
aspartate aminotransferase increased 2.8%
tooth infection 2.8%
abdominal discomfort 0%
NCT02951533 · Phase 3 · registry result, not featured evidence
nasopharyngitis 50.9%
bronchitis 9.1%
alanine aminotransferase increased 5.5%
NCT02951533 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 22.1%
upper respiratory tract infection 15.5%
headache 9%
NCT03090100 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10% (placebo 2.4%)
upper respiratory tract infection 7.5% (placebo 2.4%)
back pain 5% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
100 mg
back pain 4.8% (placebo 0%)
headache 4.8% (placebo 2.4%)
sinusitis 4.8% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
nasopharyngitis 17.9% (placebo 2.4%)
back pain 2.6% (placebo 0%)
headache 2.6% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
hypertension 7.1% (placebo 2.4%)
fatigue 4.8% (placebo 7.1%)
arthralgia 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 13.2% (placebo 2.4%)
cough 5.3% (placebo 2.4%)
upper respiratory tract infection 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
upper respiratory tract infection 7.3% (placebo 2.4%)
cough 4.9% (placebo 2.4%)
nasopharyngitis 4.9% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
back pain 2.4% (placebo 0%)
nasopharyngitis 2.4% (placebo 2.4%)
sinusitis 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
headache 9.8% (placebo 2.4%)
nasopharyngitis 9.8% (placebo 2.4%)
back pain 2.4% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 15.8% (placebo 2.4%)
upper respiratory tract infection 10.5% (placebo 2.4%)
arthralgia 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 14.6% (placebo 2.4%)
back pain 7.3% (placebo 0%)
headache 7.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

IGA 0 1 Response Visits 1.5 vs 0.7 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
PASI90 Response Visits 2.2 vs 1.1 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0 Response Visits 0.9 vs 0.4 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0/1 84.1% (n=496) vs 8.5% (n=248) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 13 more results
83.5% (n=496) vs 64.9% (n=248) Adalimumab @ 24wk100 mg
NCT02207244 · Phase 3
84.1% (n=496) vs 67.7% (n=248) Adalimumab @ 16wk100 mg
NCT02207244 · Phase 3
88.9% (n=63) vs 7.8% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
85% (n=534) vs 74.9% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
86.7% (n=534) vs 86.6% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
85.6% (n=534) vs 86.4% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.3% (n=65) vs 7.8% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
31.1% (n=135) vs 14.3% (n=133) Ustekinumab @ 28wk
NCT02203032 · Phase 3
85.1% (n=329) vs 6.9% (n=174) placebo @ 16wk
NCT02207231 · Phase 3
84.2% (n=329) vs 61.7% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
80.5% (n=329) vs 55.4% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
85.1% (n=329) vs 65.9% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
80.6% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
IGA 0 51.8% (n=496) vs 31.5% (n=248) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 5 more results
62.2% (n=534) vs 50.4% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
52.6% (n=329) vs 29.3% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
50.5% (n=329) vs 25.7% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
56.5% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
51.7% (n=60) vs 6.8% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
DLQI -11.23 vs -2.6 placebo score @ 16wk100 mg
absolute change · score
NCT02207244 · Phase 3
show 11 more results
-8.5 vs -0.8 placebo score @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-7 vs -0.4 placebo score @ 8wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-10.8 vs -2.3 placebo score @ 16wk100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-8.3 vs -0.8 placebo score @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-7.5 vs -0.4 placebo score @ 8wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-11.1 vs -2.3 placebo score @ 16wk50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-11.4 vs -2.3 placebo score @ 16wk200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-10.3 vs -2.3 placebo score @ 16wk15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-6.2 vs -2.3 placebo score @ 16wk5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-11.2 vs -0.6 placebo score @ 16wk
NCT02207231 · Phase 3
-15.2 vs -9.4 Fumaric Acid Esters score @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
PASI 75 86.3% (n=496) vs 68.5% (n=248) Adalimumab @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 14 more results
84.1% (n=63) vs 6.3% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
89.3% (n=534) vs 91.6% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.7% (n=534) vs 92.8% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
78.6% (n=42) vs 4.8% (n=42) placebo @ 16wk100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
89.2% (n=65) vs 6.3% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
81% (n=42) vs 4.8% (n=42) placebo @ 16wk50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 4.8% (n=42) placebo @ 16wk200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
75.6% (n=41) vs 4.8% (n=42) placebo @ 16wk15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
43.9% (n=41) vs 4.8% (n=42) placebo @ 16wk5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
91.2% (n=329) vs 73.1% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
5.1% (n=507) vs 22.9% (n=520) Ixekizumab @ 2wk
NCT03573323 · Phase 4 · registry result, not featured evidence
90% (n=60) vs 27.1% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
98.1% (n=54) vs 64.3% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
90% (n=60) vs 23.7% (n=59) Fumaric Acid Esters @ 32wk
NCT02951533 · Phase 3 · registry result, not featured evidence
Ss-IGA 0 1 80.6% (n=408) vs 10.9% (n=202) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
83.4% (n=277) vs 14.5% (n=145) placebo @ 16wk
NCT02207231 · Phase 3
PSSD Symptom -40.4 vs -8.3 placebo score @ 16wk100 mg
absolute change · score
NCT02207244 · Phase 3
show 1 more result
-41.9 vs -3 placebo score @ 16wk
NCT02207231 · Phase 3
PSSD Symptom Score 0 35.1% (n=410) vs 22.5% (n=200) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
36.3% (n=248) vs 21.6% (n=273) Adalimumab @ 24wk
NCT02207231 · Phase 3
PASI 100 58.2% (n=534) vs 48.4% (n=514) Secukinumab @ 48wk100 mg
responder rate · % of participants
NCT03090100 · Phase 3 · registry result, not featured evidence
show 8 more results
50% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
24.9% (n=507) vs 41.3% (n=520) Ixekizumab @ 12wk
NCT03573323 · Phase 4 · registry result, not featured evidence
1.4% (n=507) vs 6.7% (n=520) Ixekizumab @ 4wk
NCT03573323 · Phase 4 · registry result, not featured evidence
13.6% (n=507) vs 29.6% (n=520) Ixekizumab @ 8wk
NCT03573323 · Phase 4 · registry result, not featured evidence
52.3% (n=507) vs 50% (n=520) Ixekizumab @ 24wk
NCT03573323 · Phase 4 · registry result, not featured evidence
31.7% (n=60) vs 3.4% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
53.7% (n=54) vs 21.4% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
43.3% (n=60) vs 6.8% (n=59) Fumaric Acid Esters @ 32wk
NCT02951533 · Phase 3 · registry result, not featured evidence
IGA Leq2 93.5% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
NCT02905331 · Phase 3

+ 97 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT06260163 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)

Result source: NCT05528510

picankibart

Marketed by Innovent Biologics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23p19)
Partial signal

NCT05377580 · Phase 2 · completed

This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)

Result source: NCT05377580

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabpicankibart
Clinical remission (induction)22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
—Not reported
Clinical remission (maintenance)50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
—Not reported
Clinical response (induction)61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
—Not reported
Endoscopic improvement (induction)—Trial running · NCT04033445—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT04033445—Not reported

Clinical remission (induction)

guselkumab
22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
picankibart
—Not reported

Clinical remission (maintenance)

guselkumab
50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
picankibart
—Not reported

Clinical response (induction)

guselkumab
61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
picankibart
—Not reported

Endoscopic improvement (induction)

guselkumab
—Trial running · NCT04033445
picankibart
—Not reported

Corticosteroid-free remission (maintenance)

guselkumab
—Trial running · NCT04033445
picankibart
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

picankibart
Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). NCT05377580 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 4 of 4 rows · picankibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Dropout rate
2.8%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0.9%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.6%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3.8%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6.5%200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
5.6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.5%100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.7%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
2.8%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
3.1%Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
200 mg IVa
anaemia 7.4% (placebo 10.2%)
covid-19 5.6% (placebo 4.6%)
abdominal pain 3.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
200 mg IV
anaemia 6% (placebo 10.2%)
upper respiratory tract infection 4.5% (placebo 0%)
colitis ulcerative 3% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
colitis ulcerative 3.8% (placebo 2.8%)
headache 3.8% (placebo 7.4%)
anaemia 2.5% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
anaemia 5% (placebo 10.2%)
covid-19 5% (placebo 4.6%)
headache 3% (placebo 7.4%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
covid-19 7.6% (placebo 4.6%)
colitis ulcerative 4.1% (placebo 2.8%)
nasopharyngitis 2.9% (placebo 1.9%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
covid-19 7% (placebo 4.6%)
colitis ulcerative 5.4% (placebo 2.8%)
anaemia 4.7% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w to 200 mg SC q4w
colitis ulcerative 16.1% (placebo 2.8%)
covid-19 6.5% (placebo 4.6%)
abdominal pain 3.2% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
covid-19 18.4% (placebo 4.6%)
colitis ulcerative 16.8% (placebo 2.8%)
pyrexia 6.4% (placebo 4.6%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
colitis ulcerative 13.1% (placebo 2.8%)
covid-19 10.1% (placebo 4.6%)
arthralgia 8% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w to 200 mg SC q4w
covid-19 13% (placebo 4.6%)
anaemia 8.7% (placebo 10.2%)
colitis ulcerative 8.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w
covid-19 14.2% (placebo 4.6%)
colitis ulcerative 10.2% (placebo 2.8%)
arthralgia 6.1% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
400 mg IV
anaemia 8.1% (placebo 10.2%)
headache 5.4% (placebo 7.4%)
arthralgia 3.6% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.5%
upper respiratory tract infection 7%
neutropenia 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.6%
headache 7.1%
colitis ulcerative 5.7%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 1.5%
colitis ulcerative 1.5%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

Clinical Response 61.4% (n=101) vs 27.6% (n=105) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
60.7% (n=107) vs 27.6% (n=105) placebo @ 12wk400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
74.6% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
83.1% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.6% (n=421) vs 7.9% (n=280) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 4 more results
50% (n=190) vs 18.9% (n=190) placebo @ 44wk200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
45.2% (n=188) vs 18.9% (n=190) placebo @ 44wk100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
21.1% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
36.6% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · picankibart's landscape